Study of Descartes-30 in Acute Respiratory Distress Syndrome

Cartesian Therapeutics

Status and phase: Terminated; Phase 1

Conditions: Acute Respiratory Distress Syndrome; Covid19

Treatments: Biological: Descartes 30

Study type: Interventional

Funder types: Industry; NIH

Identifiers

NCT04524962

2021-MSCRFCL-5 (Other Grant/Funding Number)

DC30-1A

5R44HL158446 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19

Enrollment: 12 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must be 18 years of age or older at the time of enrollment
• Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS

Exclusion criteria

• Patient is currently enrolled into another therapeutic clinical trial with an experimental therapy that has not received marketing approval by U.S. FDA.
• Patient is in moribund state with expected survival <24 hours.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Descartes 30

Experimental group

Treatment:

Biological: Descartes 30